Compare GRPN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | CDNA |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.7M | 1.0B |
| IPO Year | 2011 | 2007 |
| Metric | GRPN | CDNA |
|---|---|---|
| Price | $12.51 | $18.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $31.25 | $27.33 |
| AVG Volume (30 Days) | ★ 879.2K | 643.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,843,877,000.00 | $48,324,000.00 |
| Revenue This Year | $4.17 | $12.18 |
| Revenue Next Year | $10.63 | $10.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $9.21 | $10.96 |
| 52 Week High | $41.26 | $21.49 |
| Indicator | GRPN | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 45.20 |
| Support Level | $11.86 | $18.30 |
| Resistance Level | $13.80 | $20.74 |
| Average True Range (ATR) | 0.70 | 1.00 |
| MACD | 0.12 | -0.11 |
| Stochastic Oscillator | 33.76 | 44.56 |
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.